ZENTALIS PHARMACEUTICALS INC. - COMMON STOCK

Zentalis Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update

17 May 2021 06:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Enters into Clinical Collaboration and Supply Agreement with GlaxoSmithKline to Evaluate its Oral WEE1 Inhibitor, ZN-c3, in Combination with Niraparib, a PARP Inhibitor

12 Apr 2021 06:00:01 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late-Breaking Session at AACR on ZN-c3, its WEE1 Inhibitor, in Patients with Advanced Solid Tumors

10 Apr 2021 12:30:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update

25 Mar 2021 06:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces Late-Breaker Oral Presentation on WEE1 Inhibitor, ZN-c3, at the AACR Annual Meeting 2021

10 Mar 2021 15:30:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals and Tempus Announce Strategic Collaboration to Advance Research and Development Capabilities

25 Feb 2021 06:00:01 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Present Initial Clinical Data on ZN-c3 at the AACR Annual Meeting 2021

24 Feb 2021 06:00:01 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces the Appointment of Dr. Enoch Kariuki to its Board of Directors

10 Feb 2021 06:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

05 Feb 2021 06:00:00 By Nasdaq GlobeNewswire

Zentalis Pharmaceuticals Announces the Initiation of Multiple Early-Stage Clinical Trials

06 Jan 2021 06:00:00 By Nasdaq GlobeNewswire